Valneva SE
VALN

$485.92 M
Marketcap
$5.99
Share price
Country
$0.17
Change (1 day)
$14.49
Year High
$5.40
Year Low
Categories

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

marketcap

P/B ratio for Valneva SE (VALN)

P/B ratio as of 2023: 10.14

According to Valneva SE's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.14. At the end of 2022 the company had a P/B ratio of 6.24.

P/B ratio history for Valneva SE from 2005 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 10.14
2022 6.24
2021 27.94
2020 25.33
2019 15.99
2018 12.95
2017 18.17
2016 18.71
2015 12.26
2014 9.73
2013 5.24
2012 16.25
2011 5.29
2010 3.89
2009 5.98
2008 5.81
2007 4.07
2006 21.91
2005 23.79